Should You Pick Vertex Stock Over Its Biotech Rivals?
Today’s big story: Anthropic IPO: Priced For 2031, Or 2036?
Vertex Pharmaceuticals (VRTX) earns the widest operating margin in a group of four biotech companies that also includes Regeneron, Alnylam and Incyte. Its stock costs more on earnings than Regeneron’s or Alnylam’s. Yet Vertex’s sales are growing the slowest of the four. The stock still returned 22.2% over the past year, well ahead of the S&P 500’s 10.3%. Regeneron did better, at 38.8%. So how much more are you paying for Vertex than for Regeneron, the closest of the three in size?

How Much More Does Vertex Stock Cost Than Regeneron?
Vertex trades at 34.1 times its earnings over the four quarters ended September 30, 2026. Regeneron trades at 20.2 times its earnings over the same quarters. That amounts to about 69% more for each dollar of profit. The extra price does not buy faster growth. Regeneron’s revenue rose 18.6% over those quarters, while Vertex’s rose 10.5%. Vertex holds an edge in how much of each sale it keeps, recording an operating margin of 33.1% against Regeneron’s 30.4%.
Alnylam is cheaper on earnings too, and its revenue grew fastest of the group, up 56.2%. Its low P/E rests on net income well above its operating income of $0.978 billion over those quarters. A $1,872 million tax benefit in fiscal Q3 2026 lifted that net income. Its stock also fell 65.2% over the past year, the worst return in the group. Incyte shows a P/E of 60.0, but it is left out of the P/E ranking. Incyte posted a net loss in fiscal Q3 2026.
| VRTX | REGN | ALNY | INCY | |
|---|---|---|---|---|
| Four Fiscal Quarters | ended 2026-09-30 (Q4 FY2025 to Q3 FY2026) | ended 2026-09-30 (Q4 FY2025 to Q3 FY2026) | ended 2026-09-30 (Q4 FY2025 to Q3 FY2026) | ended 2026-09-30 (Q4 FY2025 to Q3 FY2026) |
| Market Value (USD billion) | 135 | 97.4 | 20.9 | 24.2 |
| P/E | 34.1 | 20.2 | 7.7 | 60 (not in the P/E rank) |
| Revenue Growth | 10.5% | 18.6% | 56.2% | 24.9% |
| Operating Margin | 33.1% | 30.4% | 19.5% | 11.7% |
| Total Return, Incl. Dividends, 2025-11-14 to 2026-11-17 | 22.2% | 38.8% | -65.2% | 14.3% |
Most Of Vertex’s Sales Come From Cystic Fibrosis
The company’s main cystic fibrosis medicine, TRIKAFTA/KAFTRIO, alone brought in 85.9% of Vertex’s revenue in fiscal 2025. Sales for the drug grew less than 1% that year. On its November 2, 2026 call, management said global cystic fibrosis revenue reached $3.3 billion in fiscal Q3 2026, up 8% from a year earlier.
ALYFTREK, the newer cystic fibrosis medicine, led that growth with $706 million in worldwide sales. Management said its sales are building mainly from patients switching over from TRIKAFTA and from new patients with rarer mutations.
Medicines outside cystic fibrosis are growing, but from a small base. CASGEVY, for severe sickle cell disease, brought in $99 million in the quarter, while the acute pain medicine JOURNAVX generated $58 million.
What Has Vertex Promised For 2026?
On the same call, management raised Vertex’s fiscal 2026 revenue forecast. The new range is $13.15 billion to $13.25 billion, up from $13.1 billion to $13.2 billion. The increase reflects the Crinetics acquisition, which management expects to add $40 million to $50 million of revenue in fiscal 2026. At the midpoint, the updated forecast is about $1.2 billion more than the $12.0 billion Vertex reported for fiscal 2025. That matches roughly the pace it grew over the past four quarters.
Expenses are going up too. Management now expects about $6 billion of combined operating expenses for fiscal 2026, on its own adjusted measure. Its earlier forecast was $5.65 billion to $5.75 billion. Management attributed the increase to about $250 million of Crinetics costs. It said the business without Crinetics remains at the high end of its prior range. Vertex’s reported operating margin for fiscal Q3 2026 was 21.8%, against 40.3% a year earlier. Its research and overhead costs rose 52% in the quarter from a year earlier. In the same quarter, Regeneron’s reported operating margin was 40.5%. Vertex’s 33.1% margin over four quarters still leads the group because its three earlier quarters were stronger.
Vertex’s price appears to assume that its margin lead holds while the medicines outside cystic fibrosis grow large enough to lift its sales growth. Vertex still leads the group on margin so far, but its newer medicines remain small and its sales growth trails every peer. Its operating margin and its sales outside cystic fibrosis are the figures to watch when Vertex reports, expected in February 2027.
Vertex is a strong business, but most of its sales still come from one family of cystic fibrosis medicines. Owning many quality leaders instead of just one spreads that risk.
Why Own One Leader When You Can Own 30?
If you like finding quality companies like Vertex Pharmaceuticals, the Trefis High Quality (HQ) Portfolio holds 30 of them in equal weight. It has returned more than 105% since its September 2020 launch. You’re welcome to look inside.
Spot an error or want more like this? Tell us in 10 seconds.